The global hormonal contraceptive market was valued at $ 15,026.23 million in 2020, and is projected to reach $ 20,672.64 million by 2030, registering a CAGR of 3.3% from 2021 to 2030.
Hormonal contraceptives are birth control methods, which act on the endocrine system. These methods include use of hormones that are produced normally by women, such as estrogen and progesterone to prevent ovulation and in turn pregnancy. However, they do not provide protection against HIV or other sexually transmitted infections. There are two types of hormonal contraceptives available in the market, namely, progestin-only contraceptive and combination hormonal contraceptive. Hormonal contraception acts on the endocrine system to prevent unwanted pregnancy. Synthetic forms of naturally occurring hormones such as progestin and estrogen are used to prevent ovulation and avoid fertilization. These forms of birth control methods also change the environment of uterus, making it unfavorable for fertilization. They are available in a variety of forms such as patches, pill, injection, and rings, which are safe and reliable forms of hormonal contraceptives to prevent pregnancy.
Major factors that drive growth of the global hormonal contraceptive market include rise in focus toward family planning, health issues associated with teenage pregnancies, increase in awareness regarding modern contraception methods, and rise in use of oral pills as a key method to prevent unplanned pregnancy are expected to drive the market growth. In addition, advancements in hormonal contraception with better efficacy and fewer side effects propel the market growth. However, availability of alternate contraceptive methods, health risks associated with use of contraceptives, and lack of social acceptance restricts the market growth.
The global hormonal contraceptive market is segmented on the basis of product, hormone, age group, end user, and region. By product, the market is divided into oral contraceptive pills, injectable birth control, emergency contraceptive pills, vaginal rings, and transdermal patches. On the basis of hormones, it is divided into progestin-only contraceptive and combined hormonal contraceptive. On the basis of age group, it is divided into 15–24 years, 25–34 years, 35–44 years, and above 44 years. By end user, it is divided into hospitals, household, and clinics. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA).
The major companies profiled in the report include the Female Health Company, Teva Pharmaceutical Industries Limited, Bayer AG, Pfizer, Inc., Mylan N.V., Johnson & Johnson, Ansell LTD., Mayer Laboratories, Merck & Co., Inc., and Church & Dwight, Co., Inc.
Hormonal contraceptives are birth control methods, which act on the endocrine system. These methods include use of hormones that are produced normally by women, such as estrogen and progesterone to prevent ovulation and in turn pregnancy. However, they do not provide protection against HIV or other sexually transmitted infections. There are two types of hormonal contraceptives available in the market, namely, progestin-only contraceptive and combination hormonal contraceptive. Hormonal contraception acts on the endocrine system to prevent unwanted pregnancy. Synthetic forms of naturally occurring hormones such as progestin and estrogen are used to prevent ovulation and avoid fertilization. These forms of birth control methods also change the environment of uterus, making it unfavorable for fertilization. They are available in a variety of forms such as patches, pill, injection, and rings, which are safe and reliable forms of hormonal contraceptives to prevent pregnancy.
Major factors that drive growth of the global hormonal contraceptive market include rise in focus toward family planning, health issues associated with teenage pregnancies, increase in awareness regarding modern contraception methods, and rise in use of oral pills as a key method to prevent unplanned pregnancy are expected to drive the market growth. In addition, advancements in hormonal contraception with better efficacy and fewer side effects propel the market growth. However, availability of alternate contraceptive methods, health risks associated with use of contraceptives, and lack of social acceptance restricts the market growth.
The global hormonal contraceptive market is segmented on the basis of product, hormone, age group, end user, and region. By product, the market is divided into oral contraceptive pills, injectable birth control, emergency contraceptive pills, vaginal rings, and transdermal patches. On the basis of hormones, it is divided into progestin-only contraceptive and combined hormonal contraceptive. On the basis of age group, it is divided into 15–24 years, 25–34 years, 35–44 years, and above 44 years. By end user, it is divided into hospitals, household, and clinics. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA).
The major companies profiled in the report include the Female Health Company, Teva Pharmaceutical Industries Limited, Bayer AG, Pfizer, Inc., Mylan N.V., Johnson & Johnson, Ansell LTD., Mayer Laboratories, Merck & Co., Inc., and Church & Dwight, Co., Inc.
KEY BENEFITS FOR STAKEHOLDERS
- This report entails a detailed quantitative analysis of the current market trends from 2020 to 2023to identify the prevailing opportunities
- Market estimations are based on comprehensive analysis of the key developments in the industry
- The global market is comprehensively analyzed with respect to product, hormone type, age group, end user, and region
- In-depth analysis based on geography assists in understanding the regional market to assist in strategic business planning
- The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market
KEY MARKET SEGMENTS
By Product
- Oral Contraceptive Pills
- Injectable Birth Control
- Emergency Contraceptive Pills
- Vaginal Rings
- Transdermal Patches
By Hormones
- Progestin-only Contraceptive
- Combined Hormonal Contraceptive
By End User
- Hospitals
- Household
- Clinics
By End User
- 15–24 Years
- 25–34 Years
- 35–44 Years
- Above 44 Years
By Region
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
KEY PLAYERS
- the Female Health Company
- Teva Pharmaceutical Industries Limited
- Bayer AG, Pfizer, Inc
- Mylan NV
- Johnson & Johnson
- Ansell LTD
- Mayer Laboratories
- Merck & Co, Inc,
- Church & Dwight, Co, Inc
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
Chapter 1: Introduction
Chapter 2: Executive Summary
Chapter 3: Market Landscape
Chapter 4: Hormonal Contraceptives Market, by Product Type
Chapter 5: Hormonal Contraceptives Market, by Hormone
Chapter 6: Hormonal Contraceptives Market, by Age Group
Chapter 7: Hormonal Contraceptives Market, by End-user
Chapter 8: Hormonal Contraceptives Market, by Region
Chapter 9: Company Profiles
List of Tables
List of Figures
Executive Summary
According to a new report titled, “hormonal contraceptive Market by product type, hormones, age group, end user: global opportunity analysis and industry forecast, 2021–2030,” The global hormonal contraceptives market size was valued at $ 15,026.23 million in 2020, and is projected to reach $ 20,672.64 million by 2030, registering a CAGR of 3.3% from 2021 to 2030.Hormonal contraception acts on the endocrine system to prevent unwanted pregnancy. Synthetic forms of naturally occurring hormones such as progestin and estrogen are used to prevent ovulation and avoid fertilization. These forms of birth control methods also change environment of the uterus, making it unfavorable for fertilization. Hormonal contraceptives are available in a variety of forms such as patches, pill, injection, and rings, which are safe and reliable forms of hormonal contraceptives to prevent pregnancy. Unplanned pregnancy is more prevalent among poor and low-income population. Contraceptive drugs & devices play a major role in prevention of unwanted pregnancy. Apart from government bodies, several nonprofit organizations impart education and awareness among the population.
Increase in focus toward family planning, health issues associated with teenage pregnancies, increase in awareness regarding modern contraception methods, and rise in use of oral pills as a key method to prevent unplanned pregnancy are expected to drive the market growth. In addition, advancements in hormonal contraception with better efficacy and fewer side effects further boosts the market growth. However, availability of alternate contraceptive methods, health risks associated with the use of contraceptives and lack of social acceptance restricts the market growth.
On the basis of type, the global hormonal contraceptives market is categorized into oral contraceptive pills, injectable birth control, emergency contraceptive pills, vaginal rings, and transdermal patches. Oral contraceptive pills are expected to dominate the market throughout the forecast period, owing to rise in focus on family planning among people and continuous support from the government. Furthermore, advancements in hormonal contraception such as advent of hormonal patches, implants, and other innovative drug-device combination products fuel the market growth. Moreover, several pharmaceutical companies focus on developing products for treatment of hormonal contraceptive, which is expected to drive growth of the market during the forecast period.
On the basis of hormones, the combined hormonal contraceptive segment accounted for a major share of the share in the global hormonal contraceptives market in 2020. This segment is expected to exhibit a prominent growth rate, owing to wide availability of combined hormonal contraceptive along with better efficiency to prevent pregnancy.
On the basis of age group, the 15–24 years segment accounted for a major share of the market share in the global Hormonal contraceptives market in 2020. This segment is expected to exhibit a prominent growth rate, owing due to the, Rise in concern about adolescent sexual activity specifically due to premarital and unplanned pregnancy often leads to premature discontinuation of schooling or abortion.
On the basis of end user, the Hormonal contraceptives market is classified as hospitals, household, and clinics. the household segment accounted for more than xx% of the global market share in 2020, and is expected to remain dominant during the forecast period, owing to the wide consumption of oral pills to avoid unplanned pregnancy. In addition, increase in use of contraceptives at home has improved health-related outcomes such as maternal and infant mortality
North America accounted for more than 41% of the global market share in 2020, and is expected to remain dominant throughout the forecast period. This was attributed to increase in awareness towards the benefits of using hormonal contraceptive, high prevalence of unwanted pregnancy, and favorable regulatory scenario. Asia-Pacific is projected to register the highest CAGR of 4.5% during the forecast period, owing due to presence of populace countries such as India and China where there is greater need to control the growing population offers a lucrative opportunity for the hormonal contraceptives market growth.
The major companies profiled in the report include the Female Health Company, Teva Pharmaceutical Industries Limited, Bayer AG, Pfizer, Inc., Mylan N.V., Johnson & Johnson, Ansell LTD., Mayer Laboratories, Merck & Co., Inc., and Church & Dwight, Co., Inc.
Key Findings Of The Study
By Product type, the oral contraceptive pills segment is expected to experience rapid growth in the hormonal contraceptive market, and is projected to grow at a CAGR of 2.7% from 2021 to 2030
- By hormones, combined hormonal contraceptive segment is projected to grow at a CAGR of 29% during the forecast period
- By age group, 15-24 segment is expected to experience rapid growth in the hormonal contraceptives market, and is projected to grow at a CAGR of 37% from 2021 to 2030
Region wise, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 4.5% during the forecast period.
Companies Mentioned
- Female Health Company
- Teva Pharmaceutical Industries Limited
- Bayer AG
- Pfizer, Inc.
- Mylan N.V.
- Johnson & Johnson
- Ansell LTD.
- Mayer Laboratories
- Merck & Co., Inc.
- Church & Dwight, Co., Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 225 |
| Published | March 2022 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 15026.23 million |
| Forecasted Market Value ( USD | $ 20672.64 million |
| Compound Annual Growth Rate | 3.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
